Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Novo Nordisk

Stocks higher, inflation data In focus, Disney earnings, Nvidia chip orders, Novo Nordisk Wegovy supplies - 5 Things To Know

Stock futures higher with inflation data in focus; Core inflation easing should offset headline CPI gain; Disney shares higher following mixed Q3 earnings, planned price hikes; Nvidia sees big AI chip orders from China and Novo Nordisk warns of Wegovy supply constraints in U.S. Markets.

The Street

Is Eli Lilly Stock A Sell After Its Disastrous Third-Quarter Report?

Is Eli Lilly stock a sell after third-quarter sales of its diabetes and obesity drugs missed forecasts? Is LLY stock a sell?

Investors Business Daily

Weight-loss jabs can cut risk of heart attacks or strokes

Risk of heart attack or stroke cut by fifth, researchers say

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Dow Jones Futures Rise After Market Rally Holds Support; Two Big AI Losers

The market rally faces a key test. Nvidia is holding strong, but some Magnificent 7 stocks are ailing. Two AI plays dived late.

Investors Business Daily

Stock Market Today: Stocks Drop on Troubling China Data, Bank Ratings Worries

The main benchmarks fell Tuesday, but healthcare stocks outperformed as Eli Lilly and Novo Nordisk surged.

Kiplinger

Ozempic is in the spotlight but it's just the latest in a long and strange history of weight-loss drugs

Losing weight conveniently, cheaply, safely. That’s been the holy grail of weight-loss ever since 19th century English undertaker and weight-loss celebrity William Banting’s 1863 Letter on Corpulence spruiked his “miraculous” method of slimming down.

The Conversation

The drug “has the potential to change how obesity is regarded and treated,” the company's executive vice president for development says.

Fortune

Read news from The Economist, FT, and more,
with one subscription

Weight-loss jab can cut heart attack and stroke risk in obese adults, firm says

Wegovy manufacturer says five-year study found drug reduced major cardiovascular events by 20% in overweight or obese people

The Guardian - UK

Why The Weight-Loss Bonanza Catapulted Lilly And Novo, But Hammered Dexcom And Others

Novo Nordisk stock surged Tuesday after the firm said its weight-loss drug reduced the risk of cardiovascular events.

Investors Business Daily

Weight loss jabs can cut risk of heart attack or stroke by fifth, study suggests

The trial involved more than 17,600 people from across 41 countries.

The Independent UK

Ozempic and Wegovy maker courts prominent Black leaders to get Medicare's favor

Drugmaker Novo Nordisk focuses on Black lawmakers and opinion leaders to spread the message that obesity is a chronic disease — worth treating at a cost of $1,000 or more a month.

WEKU

Nearly half of US adults are interested in taking weight loss prescription drugs, survey finds

Ozempic, a once-weekly semaglutide injection, has grown in popularity for its weight loss side effects

The Independent UK

Novo Nordisk developed Ozempic and started a weight-loss revolution. Its next moonshot is eliminating obesity altogether

Novo’s Ozepmic and Wegovy drugs have altered the mission of the 100-year-old Danish pharma firm best known—until now—for insulin.

Fortune

Ozempic And Wegovy Side Effects Prompt Safety Concerns For Novo Nordisk

Stomach paralysis risk raises concerns over popular weight loss and diabetes drugs

Zenger

Get all your
news in one place.

100’s of premium titles.
One news app.

The Guardian - UK

Weight-loss drugs under review in UK after reports of suicidal thoughts

Ozempic and Saxenda among drugs being reviewed after five reports of suspected adverse reactions in patients

The Independent UK

Ozempic users report stomach paralysis as weight loss drug side effect: ‘I wish I never touched it’

The FDA has received reports of stomach paralysis among patients taking Ozempic and Wegovy

The Conversation

The obesity epidemic is fuelled by biology, not lack of willpower

Since the time a human first used a tool to make life easier, increased weight has been inevitable.

Investors Business Daily

AI Stocks Lead These 5 Names Near Buy Points

Artificial intelligence stocks including chipmaker Marvell Technology (MRVL), Arista Networks (ANET) and Synopsys (SNPS), which has launched AI-based chip-design tools, lead this weekend's watch list of five stocks near buy points. In addition to MRVL, ANET and SNPS stock, weight-loss drug leader Novo Nordisk (NVO) and Heico (HEI), a military…

Get all your
news in one place.

100’s of premium titles.
One news app.

Fortune

Ozempic manufacturer Novo Nordisk spent $11 million last year 'wining and dining' doctors. Experts slam the move as a breach of doctor-patient trust

Do pharmaceutical companies have influence over your doctor's prescription pad? It's relatively easy to check—but you shouldn't have to, experts say.

Investors Business Daily

Novo Nordisk Stock Today: This Diagonal Calendar Spread Trade Has Limited Risk, Unlimited Profit Potential

Concerns of weight loss and Type 1 diabetes are fueling the rise of our choice for this week's option position in shares of Novo Nordisk.

Investors Business Daily

Dow Jones Futures: Tesla Tumbles In Divided Market, But This Was The Key Loser

Tesla and Netflix were big losers in a deeply divided market Thursday, but this chip giant was the most important.

Investors Business Daily

IBD Stock Of The Day Novo Nordisk, A Weight-Loss Kingpin, Just Retook Its 50-Day Line

Novo Nordisk stock is Thursday's IBD Stock Of The Day. Shares bounded above their 50-day line, giving investors a new entry.

Investors Business Daily

S&P 500, Nasdaq Hit Fresh 52-Week Highs As Inflation Fears Ebb; Salesforce, Delta, JPMorgan In Focus: Weekly Review

The S&P 500 and Nasdaq led a strong market rally this week as inflation fears wane. Salesforce, Delta Air Lines, JPMorgan were key newsmakers

Investors Business Daily

The Blazing Weight-Loss Drug Battle: Can Anyone Unseat Undisputed Leaders Novo Nordisk And Lilly?

An overweight world is hungry for obesity treatments, driving big forecasts for weight loss drugs. For now, two pharmaceutical stocks own the market.

Investors Business Daily

The Damaging Report That Sent Weight-Loss Kingpins Novo Nordisk, Eli Lilly Into A Tailspin

Eli Lilly stock and Novo Nordisk stock skidded Tuesday on a report most patients taking weight loss drugs like Wegovy stopped within a year.

1 … 12 13 14 15

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations